Cite
Rob L, Cibula D, Knapp P, et al. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. J Immunother Cancer. 2022;10(1)doi: 10.1136/jitc-2021-003190.
Rob, L., Cibula, D., Knapp, P., Mallmann, P., Klat, J., Minar, L., Bartos, P., Chovanec, J., Valha, P., Pluta, M., Novotny, Z., Spacek, J., Melichar, B., Kieszko, D., Fucikova, J., Hrnciarova, T., Korolkiewicz, R. P., Hraska, M., Bartunkova, J., & Spisek, R. (2022). Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Journal for immunotherapy of cancer, 10(1), . https://doi.org/10.1136/jitc-2021-003190
Rob, Lukas, et al. "Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial." Journal for immunotherapy of cancer vol. 10,1 (2022). doi: https://doi.org/10.1136/jitc-2021-003190
Rob L, Cibula D, Knapp P, Mallmann P, Klat J, Minar L, Bartos P, Chovanec J, Valha P, Pluta M, Novotny Z, Spacek J, Melichar B, Kieszko D, Fucikova J, Hrnciarova T, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003190. PMID: 34992091.
Copy
Download .nbib